Indian equities ended higher on Tuesday, supported by easing geopolitical tensions and softer crude prices. A sharp drop in India VIX boost...

The Bengaluru-based firm said the new vehicle will invest between $500,000 and $3 million in IP-led firms across these sectors. The launch ...

MTBVAC, the TB vaccine, has undergone Phase I and II clinical trials in India. The vaccine has demonstrated safety and immunogenicity. Base...

Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Instit...

According to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a...

"We will be applying for licenses and (they) should come. If everything goes well, we know by next month (August). You (people) would rathe...

In a meeting held on Thursday, the SEC reviewed Bharat Biotech's application seeking grant of marketing authorisation for additional indica...

Terming the achievement as a "true success story of Atmanirbharta", he said that it was a unified effort of the government, vaccine manufac...

COVAXIN, the company's home-grown COVID-19 vaccine approved for emergency use in India, is one of two shots driving the country's massive v...

Unlike China, India is not pursuing an aggressive policy to get Covaxin approved but rather a quiet diplomacy, advising Bharat Biotech on n...

Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use...

The Brazilian Ambassador to India Andr Aranha Corra do Lago expressed keen interest on behalf of his government towards procuring the vacci...

Taking to Twitter, he said the "bayanbaazi" (remarks) between the Serum Institute and Bharat Biotech after the approval of their vaccines b...

COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Resea...

The indigenous, inactivated vaccine is being developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment faci...

Bharat Biotech has signed up 13,000 volunteers for the Phase 3 trial, backed by India's government medical research body, and is progressin...

"This is India's first phase-III efficacy study for a Covid-19 vaccine, and the largest phase-III efficacy trial ever conducted in India," ...